Previous 10 | Next 10 |
home / stock / vtyx / vtyx articles
Investors can contact the law firm at no cost to learn more about recovering their losses ?LOS ANGELES, March 11, 2024 (GLOBE NEWSWIRE) -- The...
VTX3232 was well-tolerated in the Phase 1 trial with robust target coverage achieved in both plasma and CSF; Ventyx is planning to initiate Phase ...
U.S. stocks were higher, with the Dow Jones index gaining more than 100 points on Friday. Shares of Smith & Wesson Brands, Inc. (NASDAQ: SWBI)...
NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ventyx Biosciences, Inc....
SAN DIEGO, March 07, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focu...
NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, not...
NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action law...
SAN DIEGO, March 04, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all those who...
NEW YORK, March 04, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in th...
News, Short Squeeze, Breakout and More Instantly...
Ventyx Biosciences Inc. Company Name:
VTYX Stock Symbol:
NASDAQ Market:
Ventyx Biosciences Inc. Website:
A look at the top 10 most actives in the United States Freight Technologies Inc. (FRGT) rose 10.4% to $0.6899 on volume of 220,478,071 shares Nauticus Robotics Inc. (KITT) rose 23.2% to $0.17 on volume of 217,326,595 shares GameStop Corporation (GME) rose 47.5% to $46.55 on volume of 178,...
VTX3232 demonstrated improvements in body weight, systemic inflammatory biomarkers and cardiometabolic parameters in diet-induced obesity (DIO) mice Additive effects were observed for VTX3232 in combination with the GLP-1 receptor agonist semaglutide across key endpoints compared to semag...
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced th...